<SEC-DOCUMENT>0001070081-19-000030.txt : 20190603
<SEC-HEADER>0001070081-19-000030.hdr.sgml : 20190603
<ACCEPTANCE-DATETIME>20190603164355
ACCESSION NUMBER:		0001070081-19-000030
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20190531
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20190603
DATE AS OF CHANGE:		20190603

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PTC THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001070081
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				043416587
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35969
		FILM NUMBER:		19873839

	BUSINESS ADDRESS:	
		STREET 1:		100 CORPORATE COURT
		CITY:			SOUTH PLAINFIELD
		STATE:			NJ
		ZIP:			07080-2449
		BUSINESS PHONE:		9082227000

	MAIL ADDRESS:	
		STREET 1:		100 CORPORATE COURT
		CITY:			SOUTH PLAINFIELD
		STATE:			NJ
		ZIP:			07080-2449

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PTC THERAPEUTICS INC
		DATE OF NAME CHANGE:	19980909
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a8-k6319.htm
<DESCRIPTION>8-K
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sbea9cec22fc8417980e987162942ff4e"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">WASHINGTON, D.C. 20549</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">FORM 8-K</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">CURRENT REPORT</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date of Report (Date of earliest event reported):  </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">May 31, 2019</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">PTC THERAPEUTICS, INC.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Exact Name of Company as Specified in Charter)</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:677px;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:214px;"></td><td style="width:16px;"></td><td style="width:214px;"></td><td style="width:16px;"></td><td style="width:214px;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Delaware</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">001-35969</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">04-3416587</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(State or Other Jurisdiction</font></div><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">of Incorporation)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Commission</font></div><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">File Number)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(IRS Employer</font></div><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Identification No.)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:682px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:333px;"></td><td style="width:16px;"></td><td style="width:333px;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">100 Corporate Court</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">South Plainfield, NJ</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">07080</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Address of Principal Executive Offices)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Zip Code)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Registrant&#8217;s telephone number, including area code: </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(908) 222-7000</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Not applicable</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Former Name or Former Address, if Changed Since Last Report)</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">see</font><font style="font-family:inherit;font-size:10pt;">&#32;General Instruction A.2. below):</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:5pt;">&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#32;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:5pt;">&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#32;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:5pt;">&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#32;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:5pt;">&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#32;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Emerging growth company&#160;&#160;&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160;&#160;&#160;  </font><font style="font-family:Wingdings;font-size:10pt;">o</font></div><div style="line-height:120%;padding-bottom:9px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Securities registered pursuant to Section 12(b) of the Act:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:41%;"></td><td style="width:18%;"></td><td style="width:41%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Title of each class</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Trading Symbol(s)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Name of each exchange on which registered</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common Stock, $0.001 par value per share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">PTCT</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nasdaq Global Select Market</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="s75cb36f45b5943afa9559630f90f8395"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On May 31, 2019, Christine Utter notified the Board of Directors of PTC Therapeutics, Inc. (the "Company") of her intention to transition from her roles as the Company&#8217;s principal financial officer and treasurer, effective immediately.  Ms. Utter will remain in her current role of principal accounting officer under the new title of Senior Vice President, Finance &amp; Chief Accounting Officer.  Ms. Utter&#8217;s compensation will continue at her current compensation rate. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On May 31, 2019, the Board of Directors of the Company promoted Emily Hill, the Company&#8217;s Senior Vice President, Investor Relations, to the role of Chief Financial Officer, effective immediately. In such capacity, Ms. Hill will serve as the Company&#8217;s principal financial officer and treasurer. Ms. Hill, 39, joined the Company in November 2013 as Executive Director, Investor Relations, became Vice President Investor Relations in January 2018 and Senior Vice President, Head of Investor Relations in January 2019. Prior to joining the Company, Ms. Hill was&#160;Director of Investor Relations at Warner Chilcott&#160;from 2011 to 2012. From 2008 to 2010, Ms. Hill was Senior Manager of Investor Relations at Genzyme&#160;Corporation. From 2007 to 2008,&#160;Ms. Hill&#160;was a Biotech&#160;Equity&#160;Research Associate at Summer Street Partners. Ms. Hill&#160;has a BA from Hamilton College, an MS in pharmacology from Tufts University School of Biomedical Research and received her MBA from Fordham University.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with Ms. Hill&#8217;s promotion, her base salary was increased to $415,000 annually, with a target bonus of 40% of annual salaried earnings in accordance with the terms of the Company&#8217;s annual incentive compensation plan. Ms. Hill also received, pursuant to the Company&#8217;s 2013 Long Term Incentive Plan, a one-time grant of 50,000 stock options to purchase shares of the Company&#8217;s common stock. The options will vest over four years, with 25% of the shares underlying the option vesting on the first anniversary of the grant date, and 6.25% of the shares underlying the option vesting quarterly thereafter.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ms. Hill does not have a family relationship with any of the Company&#8217;s officers or directors and has no direct or indirect interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 7.01. Regulation FD Disclosure.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 3, 2019, the Company issued a press release in which it announced the appointment of Ms. Hill described above. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated by reference into this Item 7.01.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The information set forth in or incorporated by reference into this Item 7.01, including Exhibit 99.1, shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. &#160;All website addresses given in this Report or incorporated herein by reference are for information only and are not intended to be an active link or to incorporate any website information into this Report.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;padding-left:72px;text-indent:-72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 9.01. Financial Statements and Exhibits.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(d) Exhibits</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.8984375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:17%;"></td><td style="width:6%;"></td><td style="width:77%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit No.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Description</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="a2019-06x03ptctcfoannounce.htm"><font style="font-family:inherit;font-size:10pt;">Press Release, dated June 3, 2019 issued by PTC Therapeutics, Inc.</font></a></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Signature</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:56%;"></td><td style="width:6%;"></td><td style="width:38%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PTC Therapeutics, Inc.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: June 3, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Stuart W. Peltz</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Name:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stuart W. Peltz, Ph.D.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Title:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Executive Officer</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a2019-06x03ptctcfoannounce.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s9496A69AC5F4B5DFC9041F02EF9EFFF6"></a></div><div></div><div><br></div><div style="line-height:138%;text-align:left;"><img src="a20190603ptctcfoannou_image1.gif" alt="a20190603ptctcfoannou_image1.gif" style="height:90px;width:150px;"></div><div style="line-height:138%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-weight:bold;">PTC Therapeutics Promotes Emily Hill to Chief Financial Officer</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">SOUTH PLAINFIELD, N.J., June 3, 2019 &#8211; </font><font style="font-family:inherit;font-size:11pt;">PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the promotion of Emily Hill to Chief Financial Officer. Ms. Hill joined PTC Therapeutics in</font><font style="font-family:inherit;font-size:11pt;color:#333333;">&#32;</font><font style="font-family:inherit;font-size:11pt;background-color:#ffffff;color:#333333;">November 2013 and was most recently Senior Vice President and Head of Investor Relations.</font><font style="font-family:inherit;font-size:11pt;color:#333333;">&#32;</font></div><div style="line-height:138%;padding-bottom:14px;padding-top:14px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;background-color:#ffffff;color:#333333;">&#8220;It is my pleasure to announce Emily&#8217;s promotion to CFO," said </font><font style="font-family:inherit;font-size:11pt;background-color:#ffffff;">Stuart W. Peltz, Ph.D., CEO of PTC Therapeutics, Inc. &#8220;</font><font style="font-family:inherit;font-size:11pt;background-color:#ffffff;color:#333333;">Emily has a deep knowledge of our industry and has strong relationships and understanding of the investor community.  Emily has a great track record of leadership at PTC and will be part of the executive team to deliver value to patients and shareholders as we continue to realize our vision of bringing more treatments to patients living with rare disorders.&#8221;</font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Prior to joining PTC Therapeutics, Emily was Director of Investor Relations of Warner Chilcott where she was responsible for leading the function. Additionally, Ms. Hill was Senior Manager of Investor Relations at Genzyme Corporation. Prior to Genzyme, Emily was a Biotech Equity Research Associate at Summer Street Partners. Ms. Hill has an MBA with a concentration in Finance from Fordham University, a Masters of Science in Pharmacology from Tufts University School of Biomedical Research, and a BA from Hamilton College. </font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;background-color:#ffffff;font-weight:bold;">About PTC Therapeutics, Inc.</font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">PTC is a science-led, global biopharmaceutical company focused on the discovery, development and commercialization of clinically-differentiated medicines that provide benefits to patients with rare disorders. PTC's ability to globally commercialize products is the foundation that drives investment in a robust pipeline of transformative medicines and our mission to provide access to best-in-class treatments for patients who have an unmet medical need.</font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;background-color:#ffffff;font-weight:bold;">For More Information: </font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;background-color:#ffffff;font-weight:bold;">Investors: </font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;background-color:#ffffff;">Emily Hill</font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;background-color:#ffffff;">+1 (908) 912-9327</font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;text-decoration:underline;" href="#"><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">ehill@ptcbio.com</font></a><font style="font-family:inherit;font-size:11pt;background-color:#ffffff;text-decoration:underline;">&#32;</font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;background-color:#ffffff;font-weight:bold;">Media: </font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;background-color:#ffffff;">Jane Baj</font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;background-color:#ffffff;">+1 (908) 912-9167</font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#006ebf;text-decoration:underline;">jbaj@ptcbio.com</font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Forward-Looking Statements:</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;background-color:#ffffff;color:#333333;">This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this release, other than statements of historic fact, are forward-looking statements, including statements regarding PTC's strategy, future operations, future financial position, future revenues, projected costs; and the objectives of management. Other forward-looking statements may be identified by the words "guidance", "plan," "anticipate," "believe," "estimate," "expect," "intend," "may," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions.</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;background-color:#ffffff;color:#333333;">PTC's actual results, performance or achievements could differ materially from those expressed or implied by forward-looking statements it makes as a result of a variety of risks and uncertainties, including the factors discussed in the "Risk Factors" section of PTC's most recent Quarterly Report on Form 10-Q and Annual Report on Form 10-K, as well as any updates to these risk factors filed from time to time in PTC's other filings with the SEC. You are urged to carefully consider all such factors.</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;background-color:#ffffff;color:#333333;">The forward-looking statements contained herein represent PTC's views only as of the date of this press release and PTC does not undertake or plan to update or revise any such forward-looking statements to reflect actual results or changes in plans, prospects, assumptions, estimates or projections, or other circumstances occurring after the date of this press release except as required by law.</font></div><div style="line-height:129%;padding-bottom:13px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>a20190603ptctcfoannou_image1.gif
<TEXT>
begin 644 a20190603ptctcfoannou_image1.gif
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MF#,>I1<54A!F]E<=80DR)5,$TX(NF# )@X J00K/I%.HM2ZJ12U[Y5IM450
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M=*S'!4$"HJD%F-@0H&F;YBR:4T#/ Q$#[+S.D0FJ '#. R$%Y,S/1: ^""$
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M?3;2S=N1-9\:>(9.N-UWX]UND=N;V,-ZQQ'J'8A&L^!',UI-8<C1!]_<+=\
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8\T ?]$(_]$1?]$9_]$B?]$J_]"46$  [

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
